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DIAGNOSTIC DEVICES 
Managing diabetes through the skin 
Gold-doped graphene combined with a bilayer gold mesh and polymeric microneedles forms a 
wearable sweat-based patch for real-time monitoring of glucose levels and controlled drug 
delivery.  
 
Richard Guy 
 
The global increase in diabetes is a significant physical and economic burden. Reducing the 
pernicious morbidities of the disease requires effective control of blood sugar levels through a strict 
regimen of diet and drug treatment (e.g., insulin injection)1.  Presently, glucose levels in blood or 
interstitial fluid (the solution that bathes the tissue cells) is monitored by either “finger sticks” – a 
procedure in which a finger is pricked using a lancet to obtain a small amount of blood for testing – 
or insertion of sensors through the skin. These procedures are invasive and, consequently, 
adherence to glucose monitoring by diabetics is poor. The search for a minimally or non-invasive 
method has been intense but largely unsuccessful to date. Writing in Nature Nanotechnology, Dae-
Hyeong Kim and colleagues at Seoul National University, the Institute for Basic Science in Seoul, 
MC10 Inc. in Cambridge, the University Texas, Austin, and the Advanced Institutes of 
Convergence Technologies in Gyeonggi-do, Korea, now report a ‘soft’ graphene-based 
electrochemical platform that combines real-time monitoring of blood sugar and controlled drug 
delivery for managing glucose levels2.  
 
The only minimally invasive technology for glucose monitoring to have received approval by the 
U.S. Food and Drug Administration was the GlucoWatch Biographer. The device combined an on-
board glucose sensor with reverse iontophoretic extraction of an interstitial fluid sample through 
intact skin3. It was marketed briefly in the early 2000s but was commercially unsuccessful for 
various reasons. Nonetheless, the skin interface remains an attractive target for the development 
of less intrusive glucose monitoring devices. For example, the GlucoWatch paradigm has been 
revisited in a temporary, skin-worn tattoo configuration4 and, the detection of glucose in sweat 
(provoked either by local delivery of pilocarpine or by vigorous exercise) has revealed an 
alternative route to acquire glucose data that correlate with blood sugar levels5,6. 
 
The device designed by Kim and co-workers integrates components that capture sweat from the 
skin, sensors for glucose, pH, humidity, temperature and mechanical strain, and a microneedle 
drug delivery system that responds to heat. The array of sensors is patterned onto gold-doped 
graphene and inter-connected via a serpentine gold mesh. This combination of materials and 
arrangement enhances the electrochemical activity of graphene and confers analyte selectivity and 
sensitivity. The device is flexible, mechanically robust, semi-transparent and conforms to the skin. 
When sufficient sweat is generated, typically after 10-20 minutes when the relative humidity 
reaches 80%, glucose monitoring begins. This lag-time is consistent with that reported previously 
between blood glucose levels and those in the interstitial fluid and sweat6,7. In the prototypical 
configuration illustrated in Figure 1, the graphene hybrid patch is electrically connected to a 
portable electrochemical analyser, which acts as a power source and controls the wireless transfer 
of the acquired data to a remote mobile device such as a smartphone or tablet. 
 
The detection of hyperglycaemia – through the glucose and pH sensors - is the cue for actuating 
drug delivery from the device.  The polymeric microneedles, which contain metformin (the drug 
commonly used to treat diabetes), are coated with a hydrophobic layer of tridecanoic acid. This 
layer protects the microneedles from moisture when inserted into the skin and prevents the 
premature release of metformin. When an elevated glucose level is detected, the heater 
embedded in the patch is triggered, warming the microneedles. Above the transition temperature 
of tridecanoic acid (~41°C), the underlying polymer is exposed to interstitial water and the drug is 
released. The quantity of metformin liberated in this way is step-wise and titratable by adjusting the 
number of microneedles in the device. 
 
Kim and co-workers present a substantial body of experimental data to characterise the constituent 
parts of the new device and to support its dual function in glucose monitoring and diabetes 
therapy. Proof-of-concept in human subjects is shown by the detection of high blood sugar levels 
after a meal and its reversal following normal insulin secretion.  Experiments with genetically 
diabetic mice unequivocally demonstrate that drug release upon thermal activation of polymer 
dissolution results in substantial lowering of blood sugar in these animals over the next several 
hours. 
 
There remain some important questions to answer before the technology can be translated into 
practical use.  For example, is continuous and reproducible function of the glucose sensor for 24 
hours possible?  Will the device report faithfully on glucose excursions when the wearer is actively 
sweating due to ambient temperature or vigorous exercise? How is a commercialised system to be 
configured; is it possible to identify the disposable/replaceable component(s)? And regulatory 
agencies will most certainly ask whether and how frequently sensor calibration is required; and 
what is the sensitivity to hypoglycaemia, a particular problem in juvenile diabetics?  
 
With the present design, it seems extremely unlikely that the daily adult dose of metformin can be 
delivered without an unfeasibly large number of microneedles and/or an unacceptably large patch.  
As with all transdermal delivery applications, whether passive or facilitated in some way, an 
essential criterion is that the drug is potent and that its daily dose is no more than a few milligrams.  
Nevertheless, it is probably safe to say that these issues are already being addressed and that 
other therapeutic strategies are being identified to complement the significant advances achieved 
in this work. Thus, while the Holy Grail of diabetes management – a non-invasive feedback system 
combining glucose monitoring and responsive drug delivery - is not yet quite at hand, Kim and co-
workers have certainly moved the field nearer to this coveted prize. 
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 Figure 1| Schematic diagram of the integrated glucose monitoring and diabetes therapy system.  
1) Sweat is accumulated in the patch and 2) glucose therein is monitored electrochemically on a 
graphene hybrid platform that also supports an array of other sensors (pH, humidity, mechanical 
strain). 3) In response to the detected glucose, actuation of thermo-responsive, polymeric 
microneedles is initiated, releasing an appropriate quantity of diabetes medication. 4) The 
graphene hybrid device connects electrically to a portable electrochemical analyser that acts as a 
power supply and controller that wirelessly transmits data to a remote mobile device. 
 
  
 
